USPTO serial 97320355
NEOMUNE
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- BEAUDRY-TORRES, FAITH
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with NEOMUNE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Carla B. Oakley
Carla B. Oakley MORGAN, LEWIS & BOCKIUS LLP600 Montgomery Street, Suite 2300SAN FRANCISCO, CA 94111United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceuticals for the treatment of oncological disease and disorders, cancer and tumors; pharmaceutical preparations for use in immunotherapy for the treatment of oncological disease and disorders | ACTIVE | — |
| 009 | Recorded computer software, downloadable computer software and downloadable mobile applications for data analysis for immunotherapy treatments and research; recorded computer software, downloadable computer software and downloadable mobile applications for tracking and monitoring chain of custody and chain of identity of cell therapies; recorded computer software, downloadable computer software and downloadable mobile applications for scheduling and tracking medical patient appointments, medical and healthcare services and medical laboratory services, for facilitating and handling communications between patients and providers, and providing advice and referrals in the fields of medicine, medical care, healthcare, telehealth, telemedicine, remote care and virtual health care services; recorded computer software, downloadable computer software and downloadable mobile applications for processing medication reimbursement and payer assistance services, patient support services, and hospital support services; recorded computer software, downloadable computer software and downloadable mobile applications for collecting, organizing, obtaining, and managing patient information, facilitating and handling communications between patients and providers, and providing referrals in the medical and healthcare fields; recorded computer software, downloadable computer software and downloadable mobile applications for messaging and chat in the medical and healthcare fields; recorded computer software, downloadable computer software and downloadable mobile applications for locating doctors, physician's assistants, nurses, nutritionists, therapists, healthcare professionals and healthcare service providers; recorded computer software, downloadable computer software and downloadable mobile applications for providing medical diagnosis, consultation, treatment recommendations, and medical care services and information; recorded computer software, downloadable computer software and downloadable mobile applications for managing the supply of tumor shippers, temperature monitors and GPS trackers provided to sites involved in the provision of immunotherapy treatments and cancer treatments | ACTIVE | — |
| 035 | Medical appointment scheduling services; confirming scheduled appointments for others in the field of cancer treatments; physician referral services; hospital referral services; providing online business directories featuring physicians and hospitals on the internet; processing of online orders of prescriptions in retail and central fill pharmacies; Business management in the field of clinical trials, namely, management of clinical trial information; Recruitment advertisement services, namely, posting of clinical trial notices for the purpose of recruiting patients for participation in clinical trials for the testing of medical treatments and pharmaceuticals | ACTIVE | — |
| 036 | Financial administration of patient reimbursement programs; financial administration of medication reimbursement programs and services; providing information regarding pharmaceutical cost reimbursements; providing assistance to patients regarding obtaining approval, authorization, and verification of insurance coverage for treatment, determining existing insurance benefits, and appealing from denial of insurance coverage and acquiring letters of medical necessity for insurance coverage | ACTIVE | — |
| 038 | Telecommunications services, namely, transmission of voice, audio, data, graphics, and video between patients and healthcare providers via global and local computer networks in the fields of telehealth, telemedicine, remote care, and virtual health care services; providing users with real-time and on-demand access to health care professionals via computer, telephone, and other electronic means via telecommunication networks | ACTIVE | — |
| 042 | Providing temporary use of non-downloadable computer software for scheduling and tracking medical patient appointments, medical laboratory services, medical procedures, and for matching patients and medical treatment sites, and for use in providing data analytics in field of medical research, cancer treatments and drug and immunotherapy development; providing an interactive website featuring technology that allows users to communicate with patients and manage patient treatment data, for facilitating and handling communications between patients and providers, and providing advice and referrals in the fields of medicine, medical care, healthcare, telehealth, telemedicine, remote care and virtual health care services; software as a service (SaaS) services featuring software for providing streamlined medical treatment information and improving communication among stakeholders in medical treatment and medical research; software as a service (SaaS) services featuring software for tracking and monitoring chain of custody and chain of identity of cell therapies; providing medical and scientific research information in the field of drug development and medical treatment development for delivering streamlined treatment information and improving communication among stakeholders in providing medical treatment; providing medical and scientific research information in the fields of medical research and cancer treatments; providing temporary use of online non-downloadable software for providing medical referrals; software as a service (SAAS) services featuring software for collecting, organizing, obtaining, and managing patient information, facilitating and handling communications between patients and providers, and providing advice, and referrals in the fields of medicine, medical care, healthcare, telehealth, telemedicine, remote care, and virtual health care services; software as a service (SAAS) services featuring software for scheduling medical and healthcare services; software as a service (SAAS) services featuring software for providing consultation, and medical care services and information; providing temporary use of on-line non-downloadable software for remote medical consultation in the field of telemedicine; platform as a service (PAAS) featuring computer software platforms for online collecting, organizing, obtaining, and managing patient information, facilitating and handling communications between patients and providers, and providing advice and referrals in the medical and healthcare fields; software as a service (SAAS) services featuring software for managing the supply of tumor shippers, temperature monitors and GPS trackers provided to sites involved in the provision of immunotherapy treatments and cancer treatments; providing medical and scientific research information to others in the field of pharmaceuticals and clinical trials | ACTIVE | — |
| 044 | Medical services, namely, resection of tumor and modifying cells for the treatment of cancer and other diseases and medical conditions; immunotherapy treatments; medical diagnostic and treatment services; providing information in the field of oncology and immunotherapy treatments; providing medical information, consultancy and advisory services; providing a web site featuring medical information and information relating to pharmaceuticals; providing medical and health information relating to pharmaceuticals; medical, telehealth, remote care and virtual health care services, namely, providing medical services and consultation over the telephone and via the Internet through the use of personal computers, smartphones, tablets, and mobile wireless devices via video, email, or a global computer network; providing medical services, telehealth services in the nature of telemedicine services, remote health care services, and virtual health care services via a web site and mobile app featuring health and medical information; providing telemedicine and virtual health care services for the diagnosis, consultation, and treatment of oncological or immune system conditions; medical counseling; consulting services in the field of medical care; medical, immunotherapy and pharmaceutical consultation; medical analysis services for diagnostic and treatment purposes provided by medical laboratories | ACTIVE | — |
| 045 | Providing patient advocate and case management services namely, coordinating the procurement and administration of medication in the field of oncology and immunotherapy treatments | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Iovance Biotherapeutics, Inc.
- Other trademarks owned by Iovance Biotherapeutics, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 035
- Other trademarks in Class 036
- Other trademarks in Class 038
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named NEOMUNE
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 17, 2026 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 17, 2026 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 5, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 5, 2026 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Jun 4, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Apr 7, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 7, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 7, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 9, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 8, 2026 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jun 13, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 13, 2025 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jun 12, 2025 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jun 12, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 4, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 4, 2025 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jan 4, 2025 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jan 3, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 9, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 9, 2024 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jul 9, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jul 9, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 16, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 14, 2023 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 14, 2023 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 14, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 11, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 16, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 16, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 26, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 13, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 12, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 11, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 11, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 19, 2022 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Oct 19, 2022 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Oct 19, 2022 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Oct 7, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 23, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 22, 2022 | NWAP | NEW APPLICATION ENTERED | — |